The putative actin-binding interface of myosin is separated by a large cleft that extends into the base of the nucleotide binding pocket, suggesting that it may be important for mediating the nucleotide-dependent changes in the affinity for myosin on actin. We have genetically engineered a truncated version of smooth muscle myosin containing the motor domain and the essential light chain-binding region ( At the molecular level, muscle contraction is driven by the hydrolysis of MgATP and the cyclic interaction of two proteins, actin and myosin. Myosin possesses two striking functional features that allow it to act as a molecular motor protein, namely its ability to 1) generate force and motion with actin filaments through a putative powerstroke and 2) alter its affinity for actin by more than 4 orders of magnitude at different stages of its enzymatic MgATPase cycle. The myosin MgATPase cycle can be described by a kinetic scheme (1, 2), where A, M, and AM represent actin, myosin, and the actomyosin complex, respectively (Scheme 1).
At the molecular level, muscle contraction is driven by the hydrolysis of MgATP and the cyclic interaction of two proteins, actin and myosin. Myosin possesses two striking functional features that allow it to act as a molecular motor protein, namely its ability to 1) generate force and motion with actin filaments through a putative powerstroke and 2) alter its affinity for actin by more than 4 orders of magnitude at different stages of its enzymatic MgATPase cycle. The myosin MgATPase cycle can be described by a kinetic scheme (1, 2) , where A, M, and AM represent actin, myosin, and the actomyosin complex, respectively (Scheme 1).
In Scheme 1, myosin binds strongly to actin with nanomolar affinity in the presence of MgADP or in the absence of nucleotide, and weakly to actin with micromolar affinity in the ATP and ADP⅐P i states of the contractile cycle. Thus binding of MgATP to myosin is thought to initiate the transition to the weakly bound states of the MgATPase cycle, and phosphate release is believed to be associated with the transition to the strongly bound states of the MgATPase cycle and the subsequent powerstroke. Although the biochemical basis for the ability of myosin to interact with actin in a nucleotide-dependent manner is well established (3), the structural basis for its enzymatic and motile functions are less well understood.
Crystal structures of myosin (see Fig. 1 ) solved in different nucleotide states (4 -9) , as well as other studies (3), have identified key structural rearrangements within the light chainbinding region of myosin that suggest how it may generate force and motion. However, the domain motions within the actin-binding region of myosin that are responsible for its ability to cycle between weak and strong actin-binding states during its MgATPase cycle are still unclear. Thus, examining the conformational changes that mediate the large changes in the affinity of myosin for actin during the contractile cycle are important to fully understand the molecular details of the acto-myosin interaction.
Within the putative actin-binding interface of myosin there are three main regions that are thought to interact with actin (Ref. 10; see Fig. 1 ) (amino acid residues refer to smooth muscle myosin sequence, see Ref. 11 for comparison of myosin isoforms). First, there is a highly charged surface loop (residues 628 -657) known as loop 2 or the actin-binding loop that is not visible in the crystal structures of myosin, but has been crosslinked to actin (12) and contains a proteolytic site that is protected in the presence of actin (13) . Second, a helix-loophelix motif (residues 531-561) located in the lower 50-kDa region has been implicated in forming hydrophobic contacts in a strongly bound complex with actin (14, 15) . Finally, a loop (residues 406 -416) located on the upper 50-kDa region, known as loop 3 or the "myopathy loop" because a mutation in this region in ␤-cardiac myosin causes a form of familial hypertrophic cardiomyopathy, may participate in hydrophobic contacts that mediate the change in actin affinity upon ADP release (16, 17) . The large change in affinity associated with the transition from weak to strong actin binding has been suggested to involve a conformational change in the cleft that separates the actin-binding region of myosin (i.e. the actinbinding cleft), which traverses from the nucleotide-binding site into the actin binding interface (18) . Crystal structures of myosin have predominantly shown the actin-binding cleft to be in one conformation regardless of the nucleotide bound to myosin. This conformation of the actin-binding cleft was originally referred to as open because several hydrophobic residues in the interior of the cleft are exposed to solvent and a more closed conformation was predicted based on the acto-myosin subfragment 1 (S1) cryo-EM structure in the absence of nucleotide (18) . Only a small, 10 degrees, closure of the lower 50-kDa region was observed in the presence of a few nucleotide analogs (4 -9) . On the other hand, a more recent cryo-EM reconstruction of acto-smooth muscle myosin S1 in the presence and absence of MgADP have suggested the actin-binding cleft of myosin adopts a more closed conformation compared with the structure in the absence of actin (17) . However, only indirect experimental evidence exists linking the conformation of this actinbinding cleft and affinity of myosin for actin. Thus, critical questions remain about the relationship between the structure of the actin-binding cleft and myosin function in solution. In particular, can the actin-binding cleft of myosin in solution be shown to change its conformation significantly in the transitions between the weak and strong binding states of the MgATPase cycle? And if so, does myosin bind to actin in a strongly bound complex with an actin-binding cleft that is open, partially closed, or fully closed? Finally, is actin required for conformational changes in the actin-binding cleft of myosin to be fully realized?
To address these important and unresolved questions, intrinsic tryptophan fluorescence was used to examine changes in the conformation of the actin-binding cleft during the MgATPase cycle of smooth muscle myosin. A mutant fragment of smooth muscle myosin (F425W-MDE), containing the motor domain with the essential light chain (MDE), was engineered to contain a single tryptophan located at residue 425 (normally a phenylalanine) in the upper 50-kDa subdomain of the actin-binding cleft. The intrinsic tryptophan fluorescence from F425W-MDE was used to examine changes in the environment of Trp-425 during different stages of the MgATPase cycle of myosin. In addition, we used the fluorescence signal from Trp-425 in transient kinetic experiments to directly examine the relationship of structural changes in the actin-binding cleft to transitions between the weak (AM⅐ATP, AM⅐ADP⅐Pi) and strong (AM⅐ADP, AM) actinbinding states. We have identified structural changes that occur in the actin-binding cleft upon binding nucleotide and actin, providing direct evidence for the role of this cleft in mediating the affinity of myosin for actin during muscle contraction.
EXPERIMENTAL PROCEDURES
Chemicals-Potassium chloride (KCl), sodium chloride (NaCl), beryllium chloride (BeCl 2 ), aluminum chloride (AlCl 3 ), sodium fluoride (NaF), adenosine 5Ј-triphosphate (ATP), and adenosine 5Ј-diphosphate (ADP) were purchased from Sigma. All other reagents were the highest quality available.
Solutions-A stock solution of BeCl 2 (Be, atomic absorption standard solution, in 1% HCl) was adjusted to pH 5.0 by addition of 1 N NaOH. Stock solutions of 1 M NaF were freshly prepared each day. All experiments were performed in MOPS 1 buffer, (20 mM MOPS, pH 7.4, at 25°C, 20 mM KCl, 1 mM EGTA, 1 mM MgCl 2 , 1 mM NaN 3 , and 1 mM dithiothreitol). Imidazole buffer (10 mM imidazole-HCl, pH 7.4, at 4°C, 90 mM NaCl, 1 mM NaN 3 , and 1 mM dithiothreitol) was used during protein purification (described below). A stop solution (140 mM EDTA, 20% SDS, pH 6.5) and a color developer solution (2% ammonium molybdate, 18 mM FeSO 4 ⅐7H 2 0, 0.5 M H 2 SO 4 ) were used during the steadystate ATPase assays (described below).
cDNA Construction-We performed site-directed mutagenesis on a clone of smooth muscle myosin heavy chain, containing the motor domain and truncated after the essential light chain-binding site (residues 1-819, kindly provided by Dr. Kathleen M. Trybus, University of Vermont), to produce a mutant containing a single tryptophan at residue 425. We constructed this mutant by mutating the seven endogenous MDE tryptophans to phenylalanine (or methionine in the case of Trp-546) and replacing phenylalanine 425 with a tryptophan (highlighted as a space-filling model in Fig. 1 ). We also constructed a mutant containing no tryptophans (null-MDE), and a molecule containing all seven native tryptophans (WT-MDE) as described previously (14) . The FLAG epitope sequence was attached at the C terminus of all MDE constructs for purification purposes (19) . Protein Expression and Purification-The baculovirus system was used to express all MDE constructs by co-infecting Sf9 insect cells with recombinant baculoviruses encoding the desired myosin heavy chain and essential light chain sequences. Following incubation with baculovirus for 3 days, the Sf9 cells were lysed, fractionated between 40 and 70% saturated ammonium sulfate, and dialyzed overnight in imidazole buffer at 4°C. The dialysate was bound to an anti-FLAG antibody column and eluted with the homologous peptide and dialyzed overnight into MOPS buffer with 1 mM dithiothreitol present. The degree of purity of the MDE was assessed by SDS-PAGE (20) using Coomassie-stained gels. Purified MDE concentrations (on a per head basis since MDE is a single-headed myosin construct) were determined by the method of Bradford (21) using the Bio-Rad microplate assay with WT-MDE as a standard. All experiments were performed on 2-3 different MDE preparations.
Actin was purified from chicken pectoralis muscle using an acetone powder method (22) and when necessary labeled with pyrene at Cys-374 (23) . The concentration of purified actin was determined spectophotometrically using an extinction coefficient of 0.62 mg/ml Ϫ1 cm Ϫ1 at 290 nm and the pyrene-actin concentration was determined according Pollard (23) .
Preparation of MDE-Nucleotide Analog Complexes-MDE trapped with ADP-BeF X or ADP-AlF 4 was prepared as described previously (24) . Briefly, 0.6 M purified MDE in MOPS buffer was mixed with 1 mM MgCl 2 , 3 M ADP, 2 mM NaF, and 0.2 mM AlCl 3 or BeCl 2 for 20 min at room temperature. The MDE-analog complexes formed with greater than 85% efficiency based on the inhibition of their ammonium (0.4 M NH 4 Cl, 35 mM EDTA, 25 mM Tris, pH 8.0, at 20°C) ATPase activities.
Enzymatic Assays-Steady-state actin-activated ATPase assays were performed at 37°C in low ionic strength MOPS buffer using the method of White (25) . Briefly, the ATPase reaction (0.5 ml of 1 M purified MDE in the presence of 0, 10, 30, 50, 70, and 90 M actin, final concentrations) was started by adding MgATP (2 mM final), and a 50-l aliquot of the reaction was added to 50 l of stop solution each 10 min over a 70-min period. The phosphate concentration at each time point was determined by adding 200 l of color developing solution, incubating for 20 min at room temperature, and measuring the absorbance at 700 nm in a spectrophotometer. The absorbance values were background corrected using a blank solution (the reaction mixture at time ϭ 0) and compared with a phosphate standard curve (0.1-0.7 mM inorganic phosphate). The average ATPase rates (nanomoles of P i ϫ (nmol of MDE Ϫ1 s Ϫ1 )) of three separate preparations of F425W-and WT-MDE were plotted as a function of actin concentration and fit to the MichaelisMenten equation, using a non-linear least squares method in Kaleidagraph (Synergy Software, Reading, PA), to determine the values of V max and K ATPase .
Fluorescence Measurements-A Quantamaster fluorimeter (Photon Technology International, South Brunswick, NJ) equipped with a 75-W Xenon arc lamp as an excitation source, excitation/emission monochrometers, and a WG-320 cut-off emission filter (Oriel Corp., Stratford, CT) was used to measure steady-state fluorescence from tryptophan. Tryptophan fluorescence emission spectra were measured by exciting the sample at 295 nm and collecting the emitted fluorescence from 305 to 400 nm. Excitation and emission slits were set at 2 nm. All fluorescence spectra were corrected for variations in the wavelength sensitivity of the detector system and the presence of Raman scatter 1 The abbreviation used is: MOPS, 4-morpholinepropanesulfonic acid.
and background fluorescence in the appropriate buffer solution.
The fluorescence emission spectrum of F425W-MDE was measured in the presence of 2 mM MgADP or MgATP, as well as in the absence of nucleotide. The fluorescence spectrum of F425W-MDE was also measured complexed with the nucleotide analogs, MgADP-AlF 4 Ϫ and MgADP-BeF X as described above.
Acrylamide quenching was used to determine the degree of exposure to solvent of Trp-425 in the absence and presence of various nucleotide complexes. The decrease in fluorescence intensity at the peak fluorescence emission wavelength ( max ) was measured as a function of increasing acrylamide concentrations ([Q]). Fluorescence in the absence of quencher (F 0 ) divided by the fluorescence in the presence of quencher (F) was used to quantify the relative change in fluorescence from acrylamide quenching (F 0 /F). F 0 /F was plotted as a function of [Q] and fit to the Stern-Volmer relationship, taking into account both the static (V) and dynamic (K SV ) quenching constants: (26) . The Stern-Volmer plots were fit using Kaleidagraph (Synergy Software, Reading, PA).
Kinetic Measurements-Transient kinetic measurements of tryptophan and pyrene-actin fluorescence were performed in MOPS buffer at 25°C with an Applied Photophysics (Surrey, UK) SX.18MV stoppedflow instrument. The dead time was determined to be a 1.2 ms. Tryptophan was excited at 295 nm and the fluorescence emission observed through a WG-320 cut-off filter (Oriel Corp.). Pyrene was excited at 365 nm and the fluorescence emission measured using a 400 cut-off filter (Oriel Corp.). Nonlinear least-squares fitting of the data was done with software provided with the instrument or with Kaleidagraph (Synergy Software). Errors reported are standard errors of the fits.
RESULTS AND DISCUSSION
Functional Assays-Functional assays were performed to examine the impact of the conservative mutations made to generate the smooth muscle myosin single tryptophan-containing F425W-MDE mutant. This construct displayed V max values that were reduced 2-3-fold, and K ATPase values 2-3-fold lower compared with WT-MDE, although the catalytic efficiency (k cat /K ATPase ) of F425W-MDE was virtually identical to that of WT-MDE (Table I ). In addition, F425W-MDE was found to have a high affinity for actin in the absence of nucleotide (24 nM), measured by monitoring the rate of pyrene-actin fluorescence quenching and its recovery in the presence of excess unlabeled actin (27) , that was within 8-fold of WT-MDE (3.1 nM). Previously, similar MDE mutants were shown to decorate actin with the classic arrowhead appearance as demonstrated by electron microscopy (16) and thus F425W-MDE is likely to bind actin similarly. Therefore, despite slight alterations in ATPase activity and actin binding, F425W-MDE still behaves very much like the wild-type motor protein, displaying enhanced MgATPase rates in the presence of actin with a similar catalytic efficiency to WT-MDE, and maintaining nanomolar affinity for actin in the absence of nucleotide.
Conformational Changes in the Actin-binding Cleft Monitored by Trp-425-We examined the fluorescent properties of F425W-MDE in the presence of nucleotides and nucleotide analogs to determine how the structural environment of Trp-425 is altered throughout the MgATPase cycle. The peak fluorescence emission of F425W-MDE was reduced (20%) and redshifted 5-6 nm (339 to 345 nm) in the presence of MgATP, but only slightly reduced (2%) and red-shifted (339 to 341 nm) in the presence of MgADP compared with the nucleotide-free environment ( Fig. 2A) . The fluorescence emission spectra of The maximum actin-activated ATPase (V max ) and actin concentration at which there is half-maximal activation (K ATPase ) of the mutant and wild-type constructs were determined in MOPS buffer at 37°C, assuming Michaelis-Menton kinetics. The catalytic efficiency (k cat ) was calculated from V max /K ATPase .
b The binding affinity (K D ) of F425W-and WT-MDE for actin was determined by measuring the rate of binding to and dissociation from pyrene-actin in MOPS buffer at 25°C.
FIG. 1. Structural representation of F425W-MDE (adapted from the crystal structure of Dominguez et al. (8))
. The F425W-MDE mutant of chicken gizzard smooth muscle myosin containing a single tryptophan at residue 425 was generated by first substituting all seven native tryptophans as described previously (14) and then replacing phenylalanine 425 with a tryptophan. The location of Trp-425 in the upper 50-kDa region of the actin-binding cleft of myosin is highlighted as a space-filling representation.
F425W-MDE complexed with nucleotide analogs, MgADPBeF X or MgADP-AlF 4 Ϫ , were identical to that observed in the presence of MgATP (data not shown).
To examine the solvent exposure of Trp-425 in the absence of actin in different nucleotide states we performed acrylamide quenching experiments on F425W-MDE in the presence of MgATP and MgADP, and in the absence of nucleotide (Fig. 2B) . The Stern-Volmer relationship was used to quantitatively assess the amount of acrylamide quenching (see "Experimental Procedures"). The dynamic quenching constants, indicative of the quenching that occurs by interaction of acrylamide with the excited state of Trp-425, were calculated to be 5.7 Ϯ 0.1, 4.1 Ϯ 0.1, and 4.1 Ϯ 0.1 M Ϫ1 , in the presence of MgATP and MgADP, and absence of nucleotide, respectively. Thus, in agreement with the steady-state fluorescence data, the acrylamide quenching results suggest that Trp-425 is in a more polar solventexposed environment in the nucleotide states that bind weakly to actin (M⅐ATP and M⅐ADP⅐P i ) compared with the nucleotide states that bind strongly to actin (M⅐ADP and M). Therefore, we propose that the significant change in fluorescence intensity and solvent exposure indicates that the actin-binding cleft of smooth muscle myosin adopts a more closed conformation in the strong binding states, and a more open conformation in the weak binding states, of the MgATPase cycle.
Crystallographic studies have previously identified two conformations of the actin-binding cleft of myosin. An open conformation was first observed in the chicken skeletal muscle myosin nucleotide-free structure (4) (17) have demonstrated by comparing the cryo-EM structures in the presence and absence of MgADP that the upper 50-kDa region changes conformation during ADP release, resulting in a small closure of the actin-binding cleft. We have also previously shown that the myopathy loop, which is connected to the same helix that contains Trp-425 (425-helix), changes conformation upon ADP release as well (16) . Overall, the current study, in conjunction with these two previous studies (16, 17) suggests that the MgADP-induced changes in the upper 50-kDa subdomain may mediate the 5-fold increase in actin affinity observed upon ADP release (27) . Kinetic Analysis of Conformational Changes in the Actinbinding Cleft-The transition from the strong to weak actinbinding states of the MgATPase cycle can be monitored by changes in pyrene-actin fluorescence (Table II) . The pyrene fluorescence is quenched when myosin is strongly bound to actin (AM) and recovers (indicated by an asterisk on actin in Scheme 2, A*M⅐ATP) upon formation of the weakly bound acto-myosin complex induced by MgATP binding.
We compared the time course of changes in pyrene-actin fluorescence and the intrinsic tryptophan fluorescence from F425W-MDE bound to pyrene-actin following rapid mixing with MgATP. The time course of the fluorescence change from Trp-425, which was quenched upon MgATP binding to the acto-myosin complex, was well fit by a single exponential and was hyperbolically dependent on the MgATP concentration as shown in Fig. 3A (Fig. 3B ) to structural changes in the actin-binding cleft of myosin monitored by changes in the Trp-425 fluorescence. The calculated rate constants for MgATP binding to acto-F425W-MDE are in excellent agreement with those reported in the literature for smooth muscle myosin S1 (27) . Overall, our results demonstrate that Trp-425 changes conformation during the transition from the strongly bound to weakly bound acto-myosin complex, suggesting that MgATP binding opens the actin-binding cleft which dramatically reduces the affinity of myosin for actin, causing dissociation of the acto-myosin complex.
Binding of F425W-MDE to actin increased the Trp-425 flu- 
orescence at a rate that increased linearly with actin concentrations between 1 and 5 M (Fig. 4) . Binding was modeled according to Scheme 3, where M* represents high F425W-MDE fluorescence and A* represents high pyrene-actin fluorescence. The second-order rate constant for F425W-MDE binding to actin was obtained from the slope (13 Ϯ 0.8 M Ϫ1 s Ϫ1 ) and is nearly identical to that obtained with pyrene-actin (15 Ϯ 0.3 M Ϫ1 s Ϫ1 ), which reports formation of the strongly bound complex (28) . Thus, Trp-425 is sensitive to the transition from weak to strong actin binding, consistent with closure of the actinbinding cleft upon formation of the strongly bound complex in the absence of nucleotide. More importantly, these results also suggest that actin binding stabilizes a conformation of myosin, not yet seen by crystallographic studies performed in the absence of actin, which allows for a more complete closure of the actin-binding cleft. This last conclusion arises from the fact the fluorescence signal from Trp-425 increases upon actin binding even in the absence of nucleotide, as evidenced by the stoppedflow measurements of the association kinetics between F425W-MDE and pyrene-actin. Fig. 1 ). Phosphate release is associated with closure of the cleft, which shifts Trp-425 to a more nonpolar, solvent protected conformation in the strongly bound states of the MgATPase cycle (M⅐ADP and nucleotide-free). It is unclear at this time whether phosphate release occurs prior to, simultaneously with, or immediately after cleft closure and formation of the strong actomyosin complex. However, an actomyosin⅐ADP⅐P i complex in which both the upper and lower 50-kDa subdomains are interacting with actin may be required to trigger movement of the switch II region and accelerate the release of phosphate. Furthermore, the release of MgADP from the active site appears to be associated with a more complete closure of the actin-binding cleft and stronger interactions between actin and myosin. This latter conclusion is supported by the current study, previous cryo-EM studies on the acto-smooth muscle myosin complex (17) , and previous fluorescence studies showing that the myopathy loop at the end of the 425-helix changes conformation upon MgADP release from the active site (16) . Taken together, these results suggest a pathway of communication between the active site of myosin, whose occupancy determines the nucleotide state of the MgATPase cycle, and the actin-binding interface, via the 425-helix which extends to the myopathy loop in the actin-binding region of myosin. Finally, MgATP binding to the rigor actomyosin complex reverses the structural changes in the switch II and actin-binding regions of myosin, opening the actin-binding cleft, disrupting the hydrophobic contacts between actin and myosin, and dissociating the actomyosin complex.
Model of Nucleotide and Actin-dependent Changes in the

CONCLUSIONS
In summary, our results demonstrate that the conformation of the actin-binding cleft, as probed by fluorescence changes from Trp-425, is indeed an important structural determinant for mediating the affinity of myosin for actin during the contractile cycle. Furthermore, we have shown that the actinbinding cleft of myosin adopts a unique conformation, induced by actin binding itself, which is more closed than observed previously by crystallographic studies. Thus, actin plays a critical role in the molecular mechanism of muscle contraction by inducing conformational changes in myosin required for its function as an efficient molecular motor protein.
